The importance of angiogenic markers in the differential diagnosis of HELLP syndrome vs. non-HELLP thrombocytopenia

Covadonga Quirós 1 , Francisco Suárez 1 , Belén Prieto 1 , Verónica Rodriguez 1 , Óscar Vaquerizo 2 , and Francisco V. Álvarez Menéndez 1
  • 1 Servicio de Bioquímica Clínica, Laboratorio de Medicina, Hospital Universitario central de Asturias, Oviedo, Spain
  • 2 Servicio de Obstetricia y Ginecología, Hospital Universitario central de Asturias, Oviedo, Spain
Covadonga Quirós, Francisco Suárez, Belén Prieto, Verónica Rodriguez, Óscar Vaquerizo and Francisco V. Álvarez Menéndez

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1.

    Reimer T, Rohrmann H, Stubert J, Pecks U, Glocker MO, Richter DU, et al. Angiogenic factors and acute-phase proteins in serum samples of preeclampsia and HELLP patients: a matched-pair analysis. J Matern Fetal Neonatal Med 2013;26:263–9.

    • Crossref
    • PubMed
    • Export Citation
  • 2.

    Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obst Gynecol 2004;103:981–91.

    • Crossref
    • Export Citation
  • 3.

    Sep S, Verbeek J, Koek G, Smits L, Spaanderman M, Peeters L. Clinical differences between early-onset HELLP syndrome and early-onset preeclampsia during pregnancy and at least 6 months postpartum. Am J Obstet Gynecol 2010;202:271.e1–271.e5.

    • Crossref
    • Export Citation
  • 4.

    Várbonyi T, Nagy B, Füle T, Tarca AL, Karaszi K, Schonleber J, et al. Microarray profiling reveals that placental transcriptomes of early-onset HELLP syndrome and preeclampsia are similar. Placenta 2011;32(Suppl):S21–9.

    • Crossref
    • PubMed
    • Export Citation
  • 5.

    Lindheimer MD, Umans JG. Explaining and predicting preeclampsia. New Engl J Med 2006;355:1056–8.

    • Crossref
    • Export Citation
  • 6.

    Young B, Levine RJ, Salahuddin S, Qian C, Lim KH, Karumanchi SA, et al. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 2010;23:366–70.

    • Crossref
    • PubMed
    • Export Citation
  • 7.

    Schaarschmidt W, Rana S, Stepan H. The course of angiogenic factors in early vs. late onset preeclampsia and HELLP syndrome. J Perinat Med 2013;41:511–6.

    • PubMed
    • Export Citation
  • 8.

    Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1/placental growth factor ratio as a diagnostic test for preeclampasia. Hypertension 2014;63:346–52.

    • Crossref
    • PubMed
    • Export Citation
  • 9.

    Alvarez-Fernandez I, Prieto B, Rodríguez V, Ruano Y, Escudero AI, Álvarez FV. New biomarkers in diagnosis of early onset preeclampsia and imminent delivery prognosis. Clin Chem Lab Med 2014;52:1159–68.

    • PubMed
    • Export Citation
  • 10.

    Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911–9.

    • Crossref
    • PubMed
    • Export Citation
  • 11.

    Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T, Karumanchi SA, et al. Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J Am Soc Nephrol 27:2015. JASN ASN.2015020157.

    • PubMed
    • Export Citation
Purchase article
Get instant unlimited access to the article.
$42.00
Log in
Already have access? Please log in.


or
Log in with your institution

Journal + Issues

Search